ClinicalTrials.gg
CompletedNCT07013981Updated Jun 10, 2025

The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)in Tokyo: Open Trial

An interventional study of Omega-3 polyunsaturated fatty acids and Omega-3 polyunsaturated fatty acids in Depressive Symptoms, sponsored by National Science and Technology Council, Taiwan. Completed at 1 site in Japan. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 years 8 months after the study started (first participant enrolled Jan 2013, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing omega-3 fatty acid in Depression — 2 open to participants now, 2 under way, none of them phase 3. omega-3 fatty acid · Depression.

Enrollment
22nd of 22
5 · median 67
Started
2013
with 1 other
No phase
8 of 22
2 open now
Registered
19th of 22
by date

Among the 22 studies testing omega-3 fatty acid in Depression, this one is the 22nd largest by enrollment, is one of 2 that started in 2013, is one of 8 with no phase, and was the 19th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

2 of the 22 studies testing omega-3 fatty acid in Depression are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About omega-3 fatty acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 20 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing omega-3 fatty acid in Depression, or all of them as a file.
02

Study summary

The present study aims to examine the efficacy and safety of omega-3 polyunsaturated fatty acids for pregnant women with depressive symptoms.

03

Conditions studied

  • Depressive Symptoms

Browse trials for

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. pregnant women aged 20 years or older.
  2. between 12-24 weeks gestation.
  3. a Japanese conversational ability to understand the scope of the present trial.
  4. planned to return to the hospital for checkup at 4-6 weeks after childbirth.
  5. an Edinburgh Postnatal Depression Scale (EPDS) score is 9 or more.
  6. to have good physical health judged by obstetricians.

Exclusion criteria

Exclusion Criteria:

  1. history and current suspicion of psychosis or bipolar I disorder or substance-related disorder or eating disorder or personality disorder.
  2. the item of EPDS concerning suicide ideation is 2 or more.
  3. other serious psychiatric symptoms such as self-harm behavior or in need of rapid psychiatric treatment.
  4. difficult to expect a normal birth (ex: fetal malformation etc.).
  5. having a history of bleeding disorder such as von Willebrand's Disease.
  6. regular treatment with aspirin or warfarin within the last 3 months.
  7. a smoking habit of ≥40 cigarettes per day.
  8. regular treatment with ethyl icosapentate or regular consumption of omega- 3 PUFA supplements within the last 3 months.
  9. a habit of eating fish ≥4 times per week.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Omega-3 polyunsaturated fatty acids

    1200mg EPA and 600mg DHA daily

    Dietary Supplement: Omega-3 polyunsaturated fatty acids

  • Placebo comparator
    Placebo Comparator

    320 mg olive oil and 9.9 mg omega-3 PUFAs

    Dietary Supplement: Omega-3 polyunsaturated fatty acids

Interventions

06

What researchers measure

Primary outcomes

  1. Total score of the Hamilton Rating Scale for Depression(HAMD)

    The Hamilton Rating Scale for Depression (HAMD) is a commonly used clinical tool for assessing the severity of depression. The most frequently used version, the HAMD-17, includes 17 items and has a total score range from 0 to 52. Higher scores indicate more severe depressive symptoms and thus a worse outcome, while lower scores suggest milder symptoms or improvement.

    Time frame: Twelve weeks

Secondary outcomes

  1. Total score of the Hamilton Rating Scale for Depression(HAMD)

    The Hamilton Rating Scale for Depression (HAMD) is a commonly used clinical tool for assessing the severity of depression. The most frequently used version, the HAMD-17, includes 17 items and has a total score range from 0 to 52. Higher scores indicate more severe depressive symptoms and thus a worse outcome, while lower scores suggest milder symptoms or improvement.

    Time frame: 4-6 weeks after childbirth

  2. Total scores on the Edinburgh Postnatal Depression Scale(EPDS)

    The Edinburgh Postnatal Depression Scale (EPDS) is a screening tool used to identify symptoms of postpartum depression. It consists of 10 items, each scored from 0 to 3, giving a minimum total score of 0 and a maximum total score of 30. Higher scores indicate more severe depressive symptoms, meaning a worse outcome, while lower scores suggest fewer or milder symptoms.

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  3. Total score of the Beck Depression Inventory II (BDI-II)

    The Beck Depression Inventory-II (BDI-II) is a widely used self-report questionnaire designed to assess the severity of depressive symptoms. It includes 21 items, each scored from 0 to 3, resulting in a minimum total score of 0 and a maximum total score of 63. Higher scores indicate more severe depression, meaning a worse outcome, while lower scores reflect fewer or less severe symptoms.

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  4. Major depressive disorder(MDD)as determined by the depression module of the Mini International Neuropsychiatric Interview (MINI)

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  5. Omega-3 fatty acids concentrations in erythrocytes

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  6. Brain-derived neurotrophic factor(BDNF)in serum

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  7. Estrogen in serum

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  8. Oxytocin in serum

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  9. Progesterone in serum

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  10. Human chorionic gonadotropin (hCG)in serum

    Time frame: Twelve weeks, 4-6 weeks after childbirth

  11. Phospholipase A2 in plasma

    Time frame: twelve weeks, 4-6 weeks after childbirth

Other outcomes

  1. Gestational age

    Time frame: 1 month after childbirth

  2. Gestational diabetes mellitus

    Time frame: 1 month after childbirth

  3. Gestational hypertension or preeclampsia

    Time frame: 1 month after childbirth

  4. Induced labor

    Time frame: 1 month after childbirth

  5. Estimated blood loss

    Time frame: 1 month after childbirth

  6. Cesarean section

    Time frame: 1 month after childbirth

  7. Operative vaginal delivery

    Time frame: 1 month after childbirth

  8. Birthweight

    Time frame: 1 month after childbirth

  9. 1-min and 5-min Apgar scores

    Time frame: 1 month after childbirth

07

Study locations

1 site
  • Tokyo Medicial University
    Shinjuku-Ku, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in May 2017, 52 months.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 52 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Jun 10, 2025
StartActual
Jan 9, 2013
Primary completionActual
May 11, 2017
CompletionActual
Nov 11, 2017
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07013981
Lead sponsor
National Science and Technology Council, Taiwan
Collaborators
Japanese Society for the Promotion of Science, University of Toyama, Chiba University
Responsible party
Kuan-Pin (Professor, National Science and Technology Council, Taiwan) — Principal investigator
First posted
Jun 10, 2025
Start date
Jan 9, 2013
Primary completion
May 11, 2017
Completion
Nov 11, 2017
Last update
Jun 10, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion